ICRF-159: Current status and clinical prospects
- 1 November 1977
- journal article
- research article
- Published by Elsevier in European Journal of Cancer (1965)
- Vol. 13 (11), 1293-1298
- https://doi.org/10.1016/0014-2964(77)90038-x
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Antimetastasis effect of two derivatives of epipodophyllotoxin in miceEuropean Journal of Cancer (1965), 1976
- A Study of Antitumor (Phase II) and Immunosuppressive Effects of ICRF‐159 in Patients with Metastatic MelanomaThe Journal of Clinical Pharmacology, 1976
- ICRF 159, (±) 1,2-di(3,5-dioxopiperazin-1-yl)propane NSC-129,943; RazoxaneCancer Treatment Reviews, 1976
- The bioavailability in man of ICRF-159 a new oral antineoplastic agentJournal of Pharmacy and Pharmacology, 1975
- Synergism of ICRF 159 and radiotherapy in treatment of experimental tumorsCancer, 1974
- Combined treatment of soft tissue and osteosarcomas by radiation and ICRF 159Cancer, 1974
- Mode of Action of the Cytostatic Agent ‘ICRF 159’Nature, 1970
- Biochemical studies on growth‐inhibitory bisdioxopiperazines. I. Effect on dna, rna and protein synthesis in mouse‐embryo fibroblastsInternational Journal of Cancer, 1970
- Antitumour Activity in a Series of bisDiketopiperazinesNature, 1969
- Preliminary Clinical Assessment of I.C.R.F. 159 in Acute Leukaemia and LymphosarcomaBMJ, 1969